Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Mochida Pharmaceutical Co., Ltd. ( (JP:4534) ) just unveiled an announcement.
Mochida Pharmaceutical has set the terms for a secondary offering of its common stock, establishing an offer price of 3,331 yen per share for shares to be purchased and underwritten by the underwriters, with a total offer value of approximately 3.84 billion yen. The subscription price was fixed at 3,193.60 yen per share, and settlement is scheduled for April 13, 2026, indicating a structured move to facilitate share distribution without directly raising new primary capital.
The company will also conduct an over-allotment secondary offering of 173,000 shares at the same offer price of 3,331 yen, totaling about 576 million yen, to support price stabilization and liquidity in the market. This transaction, limited to existing shares, may broaden the shareholder base and enhance trading volume, potentially improving the stock’s marketability and positioning in the Prime Market without immediate dilution from new share issuance.
The most recent analyst rating on (JP:4534) stock is a Hold with a Yen3796.00 price target. To see the full list of analyst forecasts on Mochida Pharmaceutical Co., Ltd. stock, see the JP:4534 Stock Forecast page.
More about Mochida Pharmaceutical Co., Ltd.
Mochida Pharmaceutical Co., Ltd. is a Japan-based pharmaceutical company listed on the Tokyo Stock Exchange Prime Market under securities code 4534. The company focuses on developing, manufacturing, and marketing prescription drugs and related healthcare products for the domestic and international medical markets.
YTD Price Performance: 0.52%
Average Trading Volume: 46,222
Technical Sentiment Signal: Buy
Current Market Cap: Yen119.6B
See more data about 4534 stock on TipRanks’ Stock Analysis page.